erlotinib hydrochloride has been researched along with Ascites in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HL; Chong, IW; Hsu, JF; Lee, YL; Li, CY; Lin, CM; Shen, YT; Wei, PJ; Yang, CJ | 1 |
| Ellard, SL; Fisher, B; Grimshaw, R; Hirte, H; Oza, A; Seymour, L; Swenerton, K; Tsao, M | 1 |
| Ishida, T; Katsuura, Y; Minemura, H; Misa, K; Munakata, M; Tachihara, M; Uematsu, M | 1 |
1 trial(s) available for erlotinib hydrochloride and Ascites
| Article | Year |
|---|---|
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2010 |
2 other study(ies) available for erlotinib hydrochloride and Ascites
| Article | Year |
|---|---|
Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis | 2019 |
Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Ascites; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Prednisolone; Quinazolines | 2011 |